Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma - A North American Brain Tumor Consortium Trial Article

Chang, SM, Prados, MD, Yung, WKA et al. (2004). Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma - A North American Brain Tumor Consortium Trial . CANCER, 100(8), 1712-1716. 10.1002/cncr.20157

Open Access

cited authors

  • Chang, SM; Prados, MD; Yung, WKA; Fine, H; Junck, L; Greenberg, H; Robins, HI; Mehta, M; Fink, KL; Jaeckle, KA; Kuhn, J; Hess, K; Schold, C

sustainable development goals

authors

publication date

  • April 15, 2004

webpage

published in

keywords

  • 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA
  • 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU)
  • ADULTS
  • ASTROCYTOMA
  • CARMUSTINE PLUS O-6-BENZYLGUANINE
  • CHEMOTHERAPY
  • CLINICAL-TRIALS
  • DESIGN
  • Life Sciences & Biomedicine
  • Oncology
  • RECURRENT
  • SUPRATENTORIAL MALIGNANT GLIOMA
  • Science & Technology
  • XENOGRAFTS
  • anaplastic glioma
  • neoadjuvant strategy
  • temozolamide

Digital Object Identifier (DOI)

publisher

  • JOHN WILEY & SONS INC

start page

  • 1712

end page

  • 1716

volume

  • 100

issue

  • 8